Sign In
Buy BCTX
$3.01
+0.110 (+3.79%)
At Close: Jun 22, 2026
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
07:30am, Wednesday, 10'th Dec 2025
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
07:30am, Tuesday, 09'th Dec 2025
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
Briacell Therap (BCTX) to Release Quarterly Earnings on Monday
01:20am, Monday, 08'th Dec 2025
Briacell Therap (NASDAQ: BCTX - Get Free Report) is projected to post its results before the market opens on Monday, December 15th. Analysts expect Briacell Therap to post earnings of ($12.11) per sha
Reviewing bioAffinity Technologies (NASDAQ:BIAF) and Briacell Therap (NASDAQ:BCTX)
02:14am, Sunday, 07'th Dec 2025
Briacell Therap (NASDAQ: BCTX - Get Free Report) and bioAffinity Technologies (NASDAQ: BIAF - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
07:30am, Tuesday, 02'nd Dec 2025
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025
07:30am, Tuesday, 25'th Nov 2025
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
07:30am, Thursday, 20'th Nov 2025
PHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025
07:30am, Tuesday, 18'th Nov 2025
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
07:30am, Friday, 07'th Nov 2025
Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
07:30am, Tuesday, 04'th Nov 2025
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-st
Top 3 Earnings Acceleration Buys for November
04:05pm, Monday, 27'th Oct 2025
Groupon, BriaCell Therapeutics and InnovAge stand out with accelerating earnings momentum as November's market optimism approaches.
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
07:30am, Wednesday, 22'nd Oct 2025
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-st
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
07:50am, Tuesday, 21'st Oct 2025
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
07:30am, Tuesday, 21'st Oct 2025
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
07:30am, Monday, 20'th Oct 2025
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-st
